Toward a comprehensive approach to HIV prevention for people who use drugs

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue SUPPL. 1, 2010, Pages

  Marshal, Brandon D L ^a,b   Wood, Evan ^b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

HIV; Injection drug use; Intervention; Prevention; Review

Indexed keywords

DRUG ABUSE; EPIDEMIC; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; INTRAVENOUS DRUG ABUSE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; RISK REDUCTION;

EVIDENCE-BASED MEDICINE; HIV INFECTIONS; HUMANS; INCIDENCE; SUBSTANCE-RELATED DISORDERS;

EID: 78449300220     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181f9c203     Document Type: Review

References (62)

1. Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372:1733-1745.
2. Joint United Nations Program on HIV/AIDS (UNAIDS). Report on the Global HIV/AIDS Epidemic 2008. Geneva: UNAIDS; 2008.
3. Platt L, Bobrova N, Rhodes T, et al. High HIV prevalence among injecting drug users in Estonia: implications for understanding the risk environment. AIDS. 2006;20:2120-2123.
4. Emmanuel F, Archibald C, Razaque A, et al. Factors associated with an explosive HIV epidemic among injecting drug users in Sargodha, Pakistan. J Acquir Immune Defic Syndr. 2009;51:85-90.
5. Rhodes T, Platt L, Judd A, et al. Hepatitis C virus infection, HIV coinfection, and associated risk among injecting drug users in Togliatti, Russia. Int J STD AIDS. 2005;16:749-754.
6. Des Jarlais DC, Semaan S. HIV prevention for injecting drug users: the first 25 years and counting. Psychosom Med. 2008;70:606-611.
7. Choopanya K, Des Jarlais DC, Vanichseni S, et al. Incarceration and risk for HIV infection among injection drug users in Bangkok. J Acquir Immune Defic Syndr. 2002;29:86-94.
8. Zamani S, Kihara M, Gouya MM, et al. High prevalence of HIV infection associated with incarceration among community-based injecting drug users in Tehran, Iran. J Acquir Immune Defic Syndr. 2006;42:342-346.
9. Wood E, Werb D, Marshall BDL, et al. The war on drugs: a devastating public-policy disaster. Lancet. 2009;373:989-990.
10. DeBeck K, Kerr T, Li K, et al. Incarceration and drug use patterns among a cohort of injection drug users. Addiction. 2009;104:69-76.
11. Friedman SR, Cooper HL, Tempalski B, et al. Relationships of deterrence and law enforcement to drug-related harms among drug injectors in US metropolitan areas. AIDS. 2006;20:93-99.
12. Des Jarlais DC, Hagan H, Friedman SR, et al. Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA. 1995;274: 1226-1231.
13. Des Jarlais C, Perlis T, Friedman SR, et al. Behavioral risk reduction in a declining HIV epidemic: injection drug users in New York City, 1990-1997. Am J Public Health. 2000;90:1112-1116.
14. Metzger DS, Navaline H. HIV prevention among injection drug users: the need for integrated models. J Urban Health. 2003;80:iii59-iii66.
15. World Health Organization (WHO). WHO, UNODC, UNAIDS Technical Guide for Countries to Set Targets for Universal Access to HIV Prevention, Treatment and Care for Injecting Drug Users. Geneva: WHO, UNODC, UNAIDS; 2009.
16. Merson MH, O'Malley J, Serwadda D, et al. The history and challenge of HIV prevention. Lancet. 2008;372:475-488.
17. Coates TJ, Richter L, Caceres C. Behavioral strategies to reduce HIV transmission: how to make them work better. Lancet. 2008;372:669-684.
18. Bluthenthal RN, Kral AH, Gee L, et al. The effect of syringe exchange use on high-risk injection drug users: a cohort study. AIDS. 2000;14:605-611.
19. Des Jarlais DC, Marmor M, Paone D, et al. HIV incidence among injecting drug users in New York City syringe-exchange programs. Lancet. 1996;348:987-991.
20. Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse. 2006;41:777-813.
21. Gibson DR, Flynn NM, Perales D. Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS. 2001;15:1329-1341.
22. Bluthenthal RN, Anderson R, Flynn NM, et al. Higher syringe coverage is associated with lower odds of HIV risk and does not increase unsafe syringe disposal among syringe exchange program clients. Drug Alcohol Depend. 2007;89:214-222.
23. Sorensen JL, Copeland AL. Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend. 2000;59:17-31.
24. Metzger DS, Navaline H, Woody GE. Drug abuse treatment as AIDS prevention. Public Health Rep. 1998;113:97-106.
25. Farrell M, Gowing L, Marsden J, et al. Effectiveness of drug dependence treatment in HIV prevention. Int J Drug Policy. 2005;16:S67-S75.
26. Gowing L, Farrell M, Bornemann R, et al. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2008;2:CD004145.
27. Robles RR, Reyes JC, Colon HM, et al. Effects of combined counseling and case management to reduce HIV risk behaviors among Hispanic drug injectors in Puerto Rico: a randomized controlled study. J Subst Abuse Treat. 2004;27:145-152.
28. Montaner JSG, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006;368:531-536.
29. Attia S, Egger M, Muller M, et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and metaanalysis. AIDS. 2009;23:1397-1404.
30. Wood E, Kerr T, Marshall BDI, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ. 2009;338:b1649.
31. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48-57.
32. Donoghoe MC, Bollerup AR, Lazarus JV, et al. Access to highly active antiretroviral therapy (HAART) for injecting drug users in the WHO European Region 2002-2004. Int J Drug Policy. 2007;18:271-280.
33. Wood E, Hogg RS, Lima VD, et al. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA. 2008;300:550-554.
34. Kral AH, Bluthenthal RN, Lorvick J, et al. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet. 2001;357:1397-1401.
35. Semaan S, Des Jarlais DC, Sogolow E, et al. A meta-analysis of the effect of HIV prevention interventions on the sex behaviors of drug users in the United States. J Acquir Immune Defic Syndr. 2002;30:S73-S93.
36. Wechsberg WM, Lam WK, Zule WA, et al. Efficacy of a woman-focused intervention to reduce HIV risk and increase self-sufficiency among African American crack abusers. Am J Public Health. 2004;94:1165-1173.
37. Coyle SL, Needle RH, Normand J. Outreach-based HIV prevention for injecting drug users: a review of published outcome data. Public Health Rep. 1998;113:19-30.
38. Wiebel WW, Jimenez A, Johnson W, et al. Risk behavior and HIV seroincidence among out-of-treatment injection drug users: a four-year prospective study. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12: 282-289.
39. Latkin CA. Outreach in natural settings: the use of peer leaders for HIV prevention among injecting drug users' networks. Public Health Rep. 1998;113:151-159.
40. Van Den Berg C, Smit C, Van Brussel G, et al. Full participation in harm reduction programs is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction. 2007;102:1454-1462.
41. Kidorf M, King VL, Neufeld K, et al. Improving substance abuse treatment enrollment in community syringe exchangers. Addiction. 2009; 104:786-795.
42. Milloy MJ, Wood E. Emerging role of supervised injecting facilities in human immunodeficiency virus prevention. Addiction. 2009;104:620-621.
43. Wood E, Tyndall MW, Zhang R, et al. Attendance at supervised injecting facilities and use of detoxification services. N Engl J Med. 2006;354: 2512-2514.
44. Hammett TM, Bartlett NA, Chen Y, et al. Law enforcement influences on HIV prevention for injection drug users: observations from a cross-border project in China and Vietnam. Int J Drug Policy. 2005;16:235-245. (Pubitemid 41558181)
45. DeBeck K,Wood E, Zhang R, et al. Police and public health partnerships: evidence from the evaluation of Vancouver's supervised injection facility. Subst Abuse Treat Prev Policy. 2008;3:11.
46. HammettTM,WuZ,DucTT, et al. Social evils andharmreduction: the evolving policy environment for human immunodeficiency virus prevention among injection drug users in China and Vietnam. Addiction. 2008;103:137-145.
47. Des Jarlais DC. Structural interventions to reduce HIV transmission among injecting drug users. AIDS. 2000;14:S41-S46.
48. Rhodes T, Singer M, Bourgois P, et al. The social structural production of HIV risk among injecting drug users. Soc Sci Med. 2005;61:1026-1044.
49. Latkin CA, Forman V, Knowlton A, et al. Norms, social networks, and HIV-related risk behaviors among urban disadvantaged drug users. Soc Sci Med. 2003;56:465-476.
50. Wood E, Spittal PM, Small W, et al. Displacement of Canada's largest public illicit drug market in response to a police crackdown. Can Med Assoc J. 2004;170:1551-1556.
51. Burris S, Blankenship KM, Donoghoe M, et al. Addressing the risk environment' for injection drug users: The mysterious case of the missing cop. Milbank Q. 2004;82:125-156.
52. Rhodes T, Mikhailova L, Sarang A, et al. Situational factors influencing drug injecting, risk reduction and syringe exchange in Togliatti City, Russian Federation: a qualitative study of micro risk environment. Soc Sci Med. 2003;57:39-54.
53. Small W, Kerr T, Charette J, et al. Impacts of intensified police activity on injection drug users: Evidence from an ethnographic investigation. Int J Drug Policy. 2006;17:85-95.
54. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2009. Vienna: UNODC; 2009.
55. Tyndall MW, Currie S, Spittal P, et al. Intensive injection cocaine use as the primary risk factor in theVancouverHIV-1 epidemic. AIDS. 2003;17:887-893.
56. Rawson RA, McCann MJ, Flammino F, et al. A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. Addiction. 2006;101:267-274.
57. Tempalski B, Friedman R, Keem M, et al. NIMBY localism and national inequitable exclusion alliances: the case of syringe exchange programs in the United States. Geoforum. 2007;38:1250-1263.
58. Academy for Educational Development. A Comprehensive Approach: Preventing Blood-Borne Infections Among Injection Drug Users. Atlanta: Center for Disease Control and Prevention; 2000.
59. Kidder DP, Wolitski RJ, Royal S, et al. Access to housing as a structural intervention for homeless and unstably housed people living with HIV: rationale, methods, and implementation of the housing and health study. AIDS Behav. 2007;11:S149-S161.
60. Briggs D, Rhodes T, Marks D, et al. Injecting drug use and unstable housing: scope for structural interventions in harm reduction. Drugs: Educ Prev Policy. 2009;16:436-450.
61. Bonell C, Hargreaves J, Strange V, et al. Should structural interventions be evaluated using RCTs? The case of HIV prevention. Soc Sci Med. 2006; 63:1135-1142.
62. Mathers BM, Degenhardt L, Adam P, et al. Estimating the level of HIV prevention coverage, knowledge and protective behavior among injecting drug users: what does the 2008 UNGASS reporting round tell us? J Acquir Immune Defic Syndr. 2009;52:S132-S142.